Gene therapy specialist bluebird exits “untenable” European marketEurope market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene Share XGene therapy specialist bluebird exits “untenable” European markethttps://pharmaphorum.com/news/gene-therapy-specialist-bluebird-exits-untenable-european-market/
Bluebird claims EU nod for rare disease therapy SkysonaBluebird bio has its first approval for Skysona (formerly Lenti-D), its gene therapy for children with the rare Share XBluebird claims EU nod for rare disease therapy Skysonahttps://pharmaphorum.com/news/bluebird-claims-eu-nod-for-rare-disease-therapy-skysona/
EMA finds possible link between mRNA COVID jabs and myocarditisThe EU medicines regulator has said that there is some evidence to suggest a possible link between mRNA-based Share XEMA finds possible link between mRNA COVID jabs and myocarditishttps://pharmaphorum.com/news/ema-backs-link-between-mrna-covid-jabs-and-myocarditis/
MHRA grants bluebird ‘innovation passport’ for sickle cell therapybluebird bio’s sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an ‘innovation passport’ introduced Share XMHRA grants bluebird ‘innovation passport’ for sickle cell therapyhttps://pharmaphorum.com/news/mhra-grants-bluebird-innovation-passport-for-sickle-cell-therapy/
FDA sets November review date for J&J’s multiple myeloma CAR-T cilta-celJohnson & Johnson has secured a six-month FDA review for its multiple myeloma CAR-T therapy ciltacabtagene autoleucel (cilta-cel), Share XFDA sets November review date for J&J’s multiple myeloma CAR-T cilta-celhttps://pharmaphorum.com/news/fda-sets-november-review-date-for-jjs-multiple-myeloma-car-t-cilta-cel/
New Cell & Gene Therapy Collective seeks to boost UK adoptionThe UK has been a global leader in introducing cell and gene therapies that can potentially transform the Share XNew Cell & Gene Therapy Collective seeks to boost UK adoptionhttps://pharmaphorum.com/views-and-analysis/new-cell-gene-therapy-collective-seeks-to-boost-uk-adoption/
CHMP backs bluebird bio’s gene therapy for rare disease ALDUS biotech bluebird bio has had a challenging time in the last few months, so a recommendation for Share XCHMP backs bluebird bio’s gene therapy for rare disease ALDhttps://pharmaphorum.com/news/chmp-backs-bluebird-bios-gene-therapy-for-rare-disease-ald/
bluebird bio announces long-term data from CALD gene therapybluebird bio has announced new clinical trial data from its gene therapy for patients with cerebral adrenoleukodystrophy (CALD), Share Xbluebird bio announces long-term data from CALD gene therapyhttps://pharmaphorum.com/news/bluebird-announced-long-term-data-from-cald-gene-therapy/
bluebird seeks gene therapy trial restart after cancer scarebluebird bio is to ask regulators to restart clinical studies of its LentiGlobin for sickle cell disease, after Share Xbluebird seeks gene therapy trial restart after cancer scarehttps://pharmaphorum.com/news/bluebird-seeks-gene-therapy/
